Global gains, metabolic pains: unmasking the hidden burden on liver health [0.03%]
全球收益与代谢痛苦：揭开肝脏健康的隐性负担
Maja Thiele,Ajeet Singh Bhadoria,Jessica Mellinger et al.
Maja Thiele et al.
Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial [0.03%]
基于算法的胰腺切除术后早期并发症识别和处理与常规护理相比的长期肿瘤结局：一项全国范围分阶段嵌套群随机对照试验的事后分析
Thijs J Schouten,Kyra J Prinsze,Anne Claire Henry et al.
Thijs J Schouten et al.
Background: Studies have shown that severe postoperative complications after resection of pancreatic and periampullary cancer might have a negative effect on long-term oncological outcomes. The PORSCH trial showed that an...
Jillian Horton,Edward V Loftus Jr
Jillian Horton
Cyclic exclusive enteral nutrition: a novel approach to maintaining remission in paediatric Crohn's disease [0.03%]
儿童克罗恩病维持缓解的新型营养管理策略——周期性肠内营养法
Anissa M Armet,Eytan Wine
Anissa M Armet
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial [0.03%]
儿童克罗恩病(CD-HOPE)的长期无药物缓解维持：周期性全肠内营养与部分肠内营养的对照研究
Bénédicte Pigneur,Christine Martinez-Vinson,Aurélie Bourmaud et al.
Bénédicte Pigneur et al.
Background: For children with Crohn's disease, there is a marked demand for long-term nutritional treatment strategies to avoid the side-effects related to drug treatment. We aimed to investigate whether paediatric patien...
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial [0.03%]
一项评估ALG-000184（pevifiprant钠）单药治疗慢性HBV感染受试者的I期、多中心、随机、剂量递增试验
Man-Fung Yuen,Kosh Agarwal,Alina Jucov et al.
Man-Fung Yuen et al.
Background: ALG-000184 (pevifoscorvir sodium) is a prodrug of the class-E (empty) capsid assembly modulator (CAM), ALG-001075. CAM-Es prevent hepatitis B virus (HBV) replication by inhibiting capsid assembly and pregenomi...
Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis [0.03%]
导致小肠微生物菌群失调的发生机制及病理生理学
John A Damianos,Xiao Jing Wang,Michael Camilleri
John A Damianos
Small intestinal microbial dysbiosis (SIMD) describes clinical syndromes attributed to overabundance of microbes within the small intestine. Usually attributed to bacteria (but also less commonly to archaea and fungi), SIMD arises as a seco...
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial [0.03%]
克唑替尼治疗ROS1阳性晚期非小细胞肺癌患者的疗效和安全性：一项开放性、多中心的II期研究
Millie Long,Jessica R Allegretti,Silvio Danese et al.
Millie Long et al.
Background: Approved IL-23p19 subunit inhibitors, including guselkumab, require intravenous induction dosing in patients with ulcerative colitis. We aimed to evaluate the efficacy and safety of subcutaneous guselkumab ind...